Willis Investment Counsel’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$258K Buy
1,024
+60
+6% +$12.9K 0.01% 115
2026
Q1
$210K Sell
964
-100
-9% -$22.2K 0.01% 119
2025
Q4
$243K Sell
1,064
-125
-11% -$28.5K 0.01% 121
2025
Q3
$275K Buy
1,189
+48
+4% +$9.78K 0.02% 114
2025
Q2
$212K Hold
1,141
– – 0.01% 115
2025
Q1
$239K Sell
1,141
-13
-1% -$2.53K 0.02% 109
2024
Q4
$205K Buy
1,154
+13
+1% +$2.39K 0.01% 113
2024
Q3
$225K Buy
+1,141
New +$213K 0.01% 109
2024
Q2
– Sell
-1,141
Closed -$208K – 108
2024
Q1
$208K Buy
+1,141
New +$197K 0.01% 104
2023
Q2
– Sell
-1,294
Closed -$206K – 111
2023
Q1
$206K Buy
+1,294
New +$198K 0.01% 107

Other funds holding ABBV

Willis Investment Counsel's ABBV Position: Q2 2026 in Review

Willis Investment Counsel increased its AbbVie (ABBV) stake by 6.2% in Q2 2026, buying an estimated $12.9K and bringing the position to 1,024 shares worth $258K. The position accounts for 0.01% of the portfolio, ranked #115.

Willis Investment Counsel first reported a position in ABBV in Q1 2023 and has held it in 10 quarters since. The position peaked at $275K in Q3 2025. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Willis Investment Counsel held 1,024 shares of AbbVie worth $258K as of Q2 2026.
  • Willis Investment Counsel bought 60 AbbVie shares in Q2 2026, an estimated $12.9K.
  • AbbVie made up 0.01% of Willis Investment Counsel's portfolio in Q2 2026, its #115 holding.
  • Willis Investment Counsel first reported a position in AbbVie in Q1 2023 and has held it in 10 quarters since.
  • Willis Investment Counsel's AbbVie position peaked at $275K in Q3 2025.
  • 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Willis Investment Counsel's 13F filing for Q2 2026, filed 3 Aug 2026.